ATE349226T1 - Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle - Google Patents

Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle

Info

Publication number
ATE349226T1
ATE349226T1 AT99948942T AT99948942T ATE349226T1 AT E349226 T1 ATE349226 T1 AT E349226T1 AT 99948942 T AT99948942 T AT 99948942T AT 99948942 T AT99948942 T AT 99948942T AT E349226 T1 ATE349226 T1 AT E349226T1
Authority
AT
Austria
Prior art keywords
antiplasmin
vivo
ischemic stroke
compounds
sub
Prior art date
Application number
AT99948942T
Other languages
English (en)
Inventor
Nobuo Nagai
Desire Jose Collen
Original Assignee
Leuven Res & Dev Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202004A external-priority patent/EP1062953A1/de
Application filed by Leuven Res & Dev Vzw filed Critical Leuven Res & Dev Vzw
Application granted granted Critical
Publication of ATE349226T1 publication Critical patent/ATE349226T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AT99948942T 1998-09-29 1999-09-24 Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle ATE349226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203280 1998-09-29
EP99202004A EP1062953A1 (de) 1999-06-22 1999-06-22 Verwendung von Verbindungen, die Alpha2-Antiplasmin in vivo reduzieren, zur Herstellung einer Zusammensetzung zur Behandlung ischämischer Schlaganfälle

Publications (1)

Publication Number Publication Date
ATE349226T1 true ATE349226T1 (de) 2007-01-15

Family

ID=26150731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948942T ATE349226T1 (de) 1998-09-29 1999-09-24 Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle

Country Status (12)

Country Link
US (1) US6946438B1 (de)
EP (1) EP1117437B1 (de)
JP (1) JP4577992B2 (de)
CN (1) CN1191856C (de)
AT (1) ATE349226T1 (de)
AU (1) AU6200599A (de)
CA (1) CA2344317C (de)
DE (1) DE69934595T2 (de)
DK (1) DK1117437T3 (de)
ES (1) ES2276536T3 (de)
HK (1) HK1041449B (de)
WO (1) WO2000018436A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218890A1 (en) * 2000-12-21 2002-07-01 Thromb-X N.V. A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
EP1545588A4 (de) * 2002-07-23 2007-12-05 Ludwig Inst Cancer Res Verfahren und zusammensetzungen f r die aktivierung oder hemmung von vegf-d und vegf-c
KR101161819B1 (ko) * 2004-04-22 2012-07-03 테일크리스 바이오쎄러퓨틱스 아이엔씨. 재조합적으로 변형된 플라스민
EP2220221B1 (de) 2007-11-29 2014-12-31 Grifols Therapeutics Inc. Rekombinant modifiziertes plasmin
BRPI0913397B8 (pt) * 2008-06-04 2021-05-25 Grifols Therapeutics Inc método para preparar plasmina
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
MX2012000475A (es) 2009-07-10 2012-03-26 Thrombogenics Nv Variantes de plasminogeno y plasmina.
EP2480249B1 (de) 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmin zur Behandlung von Filtrationsfehlern nach Trabeculektomie
EP2661493B1 (de) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen- und plasminvarianten
CN103764163A (zh) 2011-08-12 2014-04-30 斯路姆基因公司 纤溶酶原和纤溶酶变体
CA2846667A1 (en) * 2011-09-06 2013-03-14 Guy L. Reed Serpinf2-binding molecules and methods of use
CN106890325A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
DK3395353T5 (da) * 2015-12-18 2024-09-30 Talengen International Ltd Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
ES2961967T3 (es) 2015-12-18 2024-03-14 Talengen Int Ltd Plasminógeno para su uso en el tratamiento de la angiocardiopatía diabética
US11090372B2 (en) 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
WO2017101872A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种用于预防和治疗宫颈糜烂的方法
CN108463236A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗放射性和化学性损伤的方法
US10709771B2 (en) 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
WO2018107705A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种促进胰岛素分泌的方法
US20230134886A1 (en) * 2019-10-10 2023-05-04 University Of Kentucky Research Foundation A machine learning algorithm for predicting clinical outcomes and identifying drug targets in ischemic stroke
WO2023004626A1 (zh) * 2021-07-28 2023-02-02 北京沙东生物技术有限公司 一种骨髓瘤生物标志物serpinf2及其应用
CN114736948B (zh) * 2022-06-10 2022-11-08 深圳市帝迈生物技术有限公司 一种α2-抗纤溶酶活性测定试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
EP0937146A2 (de) * 1996-09-20 1999-08-25 The General Hospital Corporation Zusammensetzung und verfahren zur verstärkung von fibrinolyse unter verwendung von antikörpern gegen alpha2-antiplasmin

Also Published As

Publication number Publication date
CN1191856C (zh) 2005-03-09
HK1041449B (zh) 2005-08-19
EP1117437A1 (de) 2001-07-25
JP4577992B2 (ja) 2010-11-10
EP1117437B1 (de) 2006-12-27
WO2000018436A1 (en) 2000-04-06
CA2344317A1 (en) 2000-04-06
JP2002525340A (ja) 2002-08-13
CA2344317C (en) 2012-01-24
CN1320045A (zh) 2001-10-31
DK1117437T3 (da) 2007-04-10
HK1041449A1 (en) 2002-07-12
DE69934595T2 (de) 2007-10-04
DE69934595D1 (de) 2007-02-08
ES2276536T3 (es) 2007-06-16
US6946438B1 (en) 2005-09-20
AU6200599A (en) 2000-04-17

Similar Documents

Publication Publication Date Title
ATE349226T1 (de) Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
DE60024649D1 (de) Verbindungen für die behandlung von ischämie
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
ITTO950002A1 (it) Trombopoietina.
DE69909775D1 (de) Neue fettanaloge zur behandlung von diabetes
NO20006645D0 (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE60021113D1 (de) Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können
DE3882775D1 (de) Zusammensetzung zur behandlung von parodontaler krankheit.
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
BG101867A (en) Benzothiazenedioxides as endothelin antagonists
YU40002A (sh) Antipikornavirusna jedinjenja i kompozicije, njihove farmaceutske upotrebe, i materijali za njihove sinteze
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
PL329413A1 (en) Chemical compounds exhibiting properties capable to cause growth hormone release
ATE204759T1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE352310T1 (de) Verwendung von zeoliten zur herstellung oraler zubereitungen zur behandlung von vergiftung
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties